1.2062

3.90% 0.0562

Pacific Biosciences Of California Inc (PACB)

Overview News Price History Option Chain Financials Why PACB Down? Discussions Forecast

Pacific Biosciences Of California Inc stock is traded at $1.2062, with a volume of 5.33M. It is up +3.90% in the last 24 hours and down -17.02% over the past month. Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Previous Close:

$1.15

Open:

$1.15

24h Volume:

5.33M

Relative Volume:

0.82

Market Cap:

$376.11M

Revenue:

$160.03M

Net Income/Loss:

$-128.58M

P/E Ratio:

-2.8261

EPS:

-0.4268

Net Cash Flow:

$-121.21M

1W Performance:

+3.90%

1M Performance:

-17.02%

6M Performance:

-24.37%

1Y Performance:

-8.79%

1-Day Range:

$1.13

$1.225

1-Week Range:

$1.07

$1.225

52-Week Range:

$1.07

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name

Pacific Biosciences Of California Inc

Sector

Healthcare (1089)

Industry

Medical Devices (141)

Phone

650-521-8000

Address

1305 O'BRIEN DRIVE, MENLO PARK, CA

Employee

485

Twitter

@pacbio

Next Earnings Date

2026-08-05

Latest SEC Filings

PACB's Discussions on Twitter

Compare PACB vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PACB Pacific Biosciences Of California Inc	1.21	357.46M	160.03M	-128.58M	-121.21M	-0.4268
ABT Abbott Laboratories	110.08	192.51B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	332.38	130.11B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	90.66	116.83B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	51.55	75.11B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	90.78	52.80B	6.30B	1.07B	1.09B	1.8406

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-06-26	Downgrade	Barclays	Equal Weight → Underweight
Nov-11-24	Downgrade	UBS	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Buy
Apr-22-24	Downgrade	JP Morgan	Overweight → Neutral
Apr-18-24	Downgrade	Goldman	Buy → Neutral
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-14-23	Initiated	Stephens	Overweight
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-17-23	Upgrade	UBS	Neutral → Buy
Oct-31-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Jul-05-23	Resumed	JP Morgan	Overweight
Jun-30-23	Initiated	Goldman	Buy
May-10-23	Initiated	Barclays	Equal Weight
Mar-31-23	Upgrade	TD Cowen	Market Perform → Outperform
Feb-02-23	Initiated	UBS	Neutral
Jan-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-21-22	Resumed	Cantor Fitzgerald	Overweight
Jan-06-22	Resumed	Piper Sandler	Neutral
Oct-15-21	Resumed	Cowen	Market Perform
Sep-27-21	Initiated	Canaccord Genuity	Buy
Feb-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Nov-03-20	Downgrade	Piper Sandler	Overweight → Neutral
Oct-02-20	Upgrade	JP Morgan	Neutral → Overweight
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-02-20	Resumed	Cantor Fitzgerald	Overweight
Mar-09-20	Resumed	Cantor Fitzgerald	Overweight
Oct-15-19	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-02-19	Downgrade	Stephens	Overweight → Equal-Weight
Oct-19-18	Initiated	Cowen	Outperform
Nov-03-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-28-17	Downgrade	CL King	Buy → Neutral
Nov-03-16	Reiterated	Cantor Fitzgerald	Buy
Jun-27-16	Initiated	CL King	Buy
Apr-15-16	Initiated	First Analysis Sec	Overweight
Feb-04-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jan-04-16	Reiterated	Cantor Fitzgerald	Buy
Oct-23-15	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-27-15	Initiated	Cantor Fitzgerald	Buy
Feb-04-15	Reiterated	Maxim Group	Buy
Sep-26-13	Reiterated	Maxim Group	Buy
Jan-14-13	Reiterated	Maxim Group	Buy

View All

Pacific Biosciences Of California Inc Stock (PACB) Latest News

Aug 16, 2026

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - MarketBeat

Aug 16, 2026

Aug 14, 2026

ARK reports 9.59% stake in Pacific Biosciences (PACB) - Stock Titan

Aug 14, 2026

5 Must-Read Analyst Questions From PacBio’s Q2 Earnings Call - Yahoo Finance

Aug 14, 2026

Pacific Biosciences of California Inc (HAM:P09) Stock Price, Trades & News - GuruFocus

Aug 14, 2026

Aug 11, 2026

PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs - Stock Titan

Aug 11, 2026

Aug 10, 2026

Measuring – not guessing – the true path - pacb.com

Aug 10, 2026

Weekly Recap: PACB cuts 2026 revenue guide and Mark Van Oene named CEO - TradingView

Aug 10, 2026

Aug 09, 2026